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Background. Loiasis is mostly considered a relatively benign infection when compared with other filarial and parasitic diseases, 
with Calabar swellings and eyeworm being the most common signs. Yet, there are numerous reports in the literature of more serious 
sequelae. Establishing the relationship between infection and disease is a crucial first step toward estimating the burden of loiasis.
Methods. We conducted a systematic review of case reports containing 329 individuals and detailing clinical manifestations of 
loiasis with a focus on nonclassical, atypical presentations.
Results. Results indicate a high proportion (47%) of atypical presentations in the case reports identified, encompassing a wide 
range of cardiac, respiratory, gastrointestinal, renal, neurological, ophthalmological, and dermatological pathologies. Individuals 
with high microfilarial densities and residing in an endemic country were at greater risk of suffering from atypical manifestations.
Conclusions. Our findings have important implications for understanding the clinical spectrum of conditions associated with 
Loa loa infection, which extends well beyond the classical eyeworm and Calabar swellings. As case reports may overestimate the true 
rate of atypical manifestations in endemic populations, large-scale, longitudinal clinico-epidemiological studies will be required to 
refine our estimates and demonstrate causality between loiasis and the breadth of clinical manifestations reported. Even if the rates of 
atypical presentations were found to be lower, given that residents of loiasis-endemic areas are both numerous and the group most at 
risk of severe atypical manifestations, our conclusions support the recognition of loiasis as a significant public health burden across 
Central Africa.
Keywords. atypical clinical manifestations; case reports; Loa loa; microfilaremia; systematic review.
The filarial nematode Loa loa, transmitted between humans 
by Chrysops (tabanid) flies, causes loiasis, a disease endemic 
to forested areas of Central Africa [1]. An estimated 14 mil-
lion people currently reside in high-risk areas (where L.  loa 
microfilaremia prevalence is ≥20%), for example, in Cameroon, 
Gabon, and Democratic Republic of the Congo [2]. Loiasis is 
known for 2 hallmark signs, namely “Calabar” swellings (local-
ized transient subcutaneous swellings) and adult worm migra-
tion under the bulbar conjunctiva (“eyeworm”). Despite being 
highly prevalent across parts of Central Africa, and estimated 
as the third most common reason for medical consultation 
in heavily affected areas, loiasis is perceived as a relatively be-
nign condition [3]. In contrast to other filariases such as on-
chocerciasis and lymphatic filariasis, it remains absent from the 
World Health Organization’s list of prioritized neglected trop-
ical diseases [4]. A recently demonstrated association between 
heavy microfilarial carriage and increased human mortality [5] 
has led to calls for recognition of loiasis as a significant public 
health problem [6].
Research on loiasis has been primarily concerned with the 
impediment it poses to mass treatment with ivermectin for 
the control of onchocerciasis in Central Africa [7]; individ-
uals with high levels of circulating microfilariae (mf; the adult 
worm’s progeny) in the blood have an increased risk of devel-
oping severe adverse events (SAEs) after microfilaricidal treat-
ment [8, 9]. Research on clinical manifestations has focused 
on Calabar swellings and eyeworm migration, including work 
from endemic areas [10, 11] and retrospective syntheses of 
cases presenting to clinical consultation in nonendemic coun-
tries [12–18]. However, the full spectrum of clinical manifest-
ations remains poorly defined, with an array of both benign and 
severe cardiac, respiratory, renal, gastrointestinal, ophthalmic, 
neurological, and other manifestations having been observed in 
individual case reports.
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Aiming to characterize the full spectrum of disease associ-
ated with loiasis and explore its determinants, we undertook a 
systematic review and analysis of published case reports con-
taining individual patient data (IPD) on clinical manifestations. 
We present an overview of the atypical disease manifestations 
of loiasis (defined as presentations featuring signs other than 
Calabar swellings and/or eyeworm) and assess the influence 
of different factors on the propensity of individuals to present 
typically (Calabar swellings and/or eyeworm) or atypically (all 
other manifestations attributed to loiasis by the reviewed pa-
pers’ authors).
METHODS
Systematic Review
We conducted a systematic review of published case reports 
and case series containing IPD on loiasis, without any restric-
tions on publication dates. The search, carried out in Embase, 
Medline (PubMed), Global Health, Web of Science, and Scopus 
on December 22, 2017, used the following medical subject head-
ings: “Loa loa” or “loiasis” or “loaiasis” or “filaria* loa” or “loa 
filaria*” or “eyeworm*” or “eye worm*” or “calabar swelling*.”
Three of the 5 databases could be searched using predefined 
subject headings. In Embase and Global Health, “Loa,” “Loa 
loa,” and “loiasis” were used. For Medline (Pubmed), “Loa” and 
“loiasis” were selected. For these, subject headings were com-
bined with medical subject headings using the “OR” function.
The search yielded 5965 articles; 3651 duplicates were re-
moved. Case reports and case series containing IPD written 
in English, French, Spanish, German, Italian, Romanian, and 
Dutch were independently reviewed for eligibility by 2 au-
thors. Articles were excluded if the patient did not show evi-
dence of Loa loa infection (defined as the presence/history 
of subconjunctival or subcutaneous adult worm migration, 
Calabar swellings, microfilaremia, or parasite identification 
following worm extraction, if undertaken) or when the manu-
script contained insufficient IPD metadata (eg, no information 
on cause of consultation, clinical presentation, or diagnostic 
methods used). Disagreements were resolved by discussion 
and, if required, arbitration by a third author. A total of 279 ar-
ticles were retained for data extraction and analysis (Figure 1). 
The full list of included papers is given in the Supplementary 
Data (“Literature Review”). The protocol was registered pro-
spectively with PROSPERO [International Prospective Register 
of Systematic Reviews] (March 4, 2018, CRD42018092232) and 
followed the guidelines set out by PRISMA [Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses]  for system-
atic reviews of IPD.
5965 records identified through
database searching:
- Embase - 1640
- Medline - 1167
- Global Health - 1009
- Web of  Science 804
- Scopus 1345
2314 titles and abstracts screened
after duplicates removed
374 full-text articles screened
279 studies with individual
patient data included
3651 duplicates excluded
1940 articles excluded due to being in
a language other than English, French,
Spanish, German, Italian, Romanian, or
Dutch; manuscripts on patients
without individual patient data or
Loa loa infection
95 articles excluded using
exclusion criteria:
- 39 papers could not be located
- 40 papers had insucient patient
  data
- 8 papers were not case reports
  or case series
- 8 papers did not have a clear
  diagnosis of  loiasis
Figure 1. Systematic review methodology. Flow diagram showing the number of papers identified, screened, assessed for eligibility, and included in the systematic review 
of individual patient data from loiasis case reports.
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Patient Characteristics
Three authors independently extracted de-identified IPD: pa-
tient demographics (age, sex, residency status), physical ex-
amination, manifestations attributed to loiasis, blood tests 
(including eosinophilia and assessment of microfilaremia), di-
agnostic imaging, histopathology, and treatment. Antifilarial 
treatment offered to patients included diethylcarbamazine 
(DEC; most frequently), ivermectin, albendazole, mebendazole, 
and imatinib. Where particular data were not available for 
a given patient, manifestations not reported by the paper’s 
author(s) were considered to be absent. Co-infections were also 
recorded.
The residency status of patients was assigned to 3 categories: 
locals residing in an endemic country (born and living in an en-
demic region), locals residing in a nonendemic country (born 
in an endemic region but living in a nonendemic region at the 
time of consultation), and expatriates (born in a nonendemic 
region but having spent a period of time in an endemic region). 
Manifestations were categorized into typical (Calabar swelling 
and eyeworm) and atypical (all other manifestations attrib-
uted to loiasis, including nonclassical ocular signs). When 
microfilarial densities were available, individuals were assigned 
to 1 of the following 3 categories: zero (amicrofilaremic individ-
uals, with no detectable mf), low (>0 but <8000 mf/mL blood), 
or high (≥8000 mf/mL blood). The threshold of 8000 mf/mL was 
chosen, as individuals with higher densities have an increased 
risk of marked adverse events (ie, functional impairment for 
several days) after ivermectin treatment [8]. Eosinophilia was 
defined as a peripheral eosinophil blood count >0.5×109 cells or 
a peripheral blood eosinophil count ≥6% [19].
Data Analysis
Descriptive statistical analyses (%  of cases with each condi-
tion by organ system) were undertaken to characterize the full 
spectrum of clinical conditions associated with L. loa infection. 
Pearson’s chi-square test was used to assess whether the propor-
tion of patients presenting atypically varied across the different 
microfilarial density categories. Multivariable logistic regres-
sion models were used to investigate the existence of associ-
ations between demographic factors (age, sex, residency status), 
microfilarial density, and type of presentation (atypical or typ-
ical), yielding odds ratio (OR) values and their associated 95% 
confidence intervals (CIs). The statistical methodology is de-
scribed in the Supplementary Data (“Statistical Analyses”). All 
analyses were conducted using R, version 3.4.4 (https://www.r-
project.org/).
RESULTS
Patient Demographics
Data from 329 patients were obtained. A total of 169 patients 
(51.4%) were classified as locals, 156 (47.4%) as expatriates, 
and 4 (1.2%) could not be assigned due to missing information. 
From the local patients, 61 (36.1%) were living in an endemic 
country, 99 (58.6%) were not living in an endemic country at 
the time of presenting, and 9 (5.3%) could not be classified due 
to missing information. A  total of 148 patients (45.0%) were 
female, 170 (51.7%) were male, and there were 11 (3.3%) in-
stances in which the patient’s sex was not stated. The patient’s 
age was reported in 302 (91.8%) cases, with a median (inter-
quartile range [IQR]) of 32 (24–41) years.
Clinical Manifestations
A total of 175 (53.2%) patients had only typical manifestations: 
47 patients with Calabar swellings, 77 with eyeworm, and 51 
patients with both Calabar swellings and eyeworm. In com-
parison, 154 (46.8%) had at least 1 atypical manifestation, of 
which 29 patients had manifestations spanning 2 different body 
systems (Figure 2). No patients presented with atypical mani-
festations spanning 3 or more organ systems. (In the following, 
citations preceded by S refer to Supplementary References in 
the Supplementary Data, “Literature Review.”)
Eight patients (5.2%) had heart failure signs [S11, S97, 
S155, S184, S208, S217, S221], of which 4 were caused by 
endomyocardial fibrosis [S97, S155, S184, S221]. Ten patients 
(6.5%) had respiratory system manifestations. Six were caused 
by pleural effusion [S39, S53, S74, S80, S228, S229]; 5 contained 
mf in the pleural fluid [S39, S53, S74, S228, S229], and 1 dem-
onstrated mf on broncho-alveolar lavage (BAL) [S80]. Five of 
6 patients had resolution of the pleural effusion after receiving 
antifilarial treatment [S39, S74, S228, S229]. Three patients had 
signs caused by pulmonary fibrosis [S72, S137, S186], with 1 
patient demonstrating mf on BAL [S137]. One patient suffered 
from acute respiratory distress syndrome, although it was un-
clear if loiasis was responsible [S44].
Ten patients (6.5%) had gastrointestinal system manifest-
ations [S6, S35, S49, S51, S70, S74, S100, S124]. Two patients 
had ascites [S74, S79]; 1 contained mf in the ascitic fluid, which 
resolved with antifilarial treatment [S79]. Microfilariae were in-
cidentally discovered in 2 patients during a gastric [S6] and per-
itoneal lavage [S51]. Three patients had hypo-echogenic splenic 
lesions [S35, S100], of which 2 were associated with spleno-
megaly [S35]. One subsequent splenectomy demonstrated mf 
on spleen histology. One patient had bowel obstruction caused 
by constricting, thickened, and fibrotic lesion of the descending 
colon, containing mf [S124]. One patient had polyps containing 
mf upon resection [S70]. Finally, 1 patient suffered from acute 
hepatitis that improved with antifilarial therapy [S79].
Fifteen patients (9.7%) had renal system manifestations [S12, 
S62, S77, S89, S116, S149, S169, S192, S201, S224, S227, S234, 
S256, S258, S268], ranging in severity from asymptomatic pro-
teinuria to severe nephrotic syndrome and end-stage renal 
failure. In the 8 cases where a renal biopsy was performed for 
the investigation of nephrotic syndrome [S77, S89, S116, S149, 
S224, S227, S234], membranous glomerulonephropathy was 
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shown in all but 2 cases, in which focal interstitial inflamma-
tion [S227] and focal segmental glomerulosclerosis [S234] were 
shown. One patient suffered from renal failure secondary to in-
terstitial fibrosis and sclerosis of the glomeruli [S89]. Four pa-
tients had microfilaruria (mf in urine [S12, S89, S256, S258]), 
and 3 had mf on histopathology analysis of their renal biopsy 
[S62, S224, S234].
Nine patients (5.8%) had reproductive system manifestations 
[S22, S38, S124, S131, S164, S220, S226]. Microfilariae were 
isolated from a sample of follicular fluid in 2 infertile women 
[S22, S226] and incidentally found in 3 women during a cervical 
smear [S38, S164, S220]. Three men were found to have an adult 
worm in their testicles (tunica vaginalis or spermatid cord) after 
orchidectomy due to testicular swelling [S124]. Seven (4.5%) 
women had mammogram results that were highly suggestive 
of the presence of a L.  loa worm, reporting linear, straight, or 
curved calcifications 0.3–2.5  cm in length [S92, S117, S140, 
S166, S210, S216]. The indication for mammogram varied, with 
4 undergoing routine screening, 2 for a painful breast lump, and 
1 for bilaterally painful breasts. Two women had excisions per-
formed [S117, S166], and in 1 an adult L. loa was isolated [S117].
Nineteen patients (12.3%) had joint-related manifestations 
[S8, S34, S37, S43, S103, S107, S120, S128, S135, S148, S150, 
S151, S174, S183, S193, S205, S232]. Five patients were assessed 
for an acute septic joint [S8, S34, S107, S128, S151]. Of the 4 
patients whose joints were aspirated for articular fluid, 2 dem-
onstrated mf in the synovial fluid [S107, S128], and the other 2 
other showed eosinophilia between 60% and 80% [S34, S151]. 
Five patients demonstrated dead calcified worms on x-ray in 
painful wrist and finger joints [S37, S103, S120, S150]. Four 
patients experienced severe arthralgic joint pains that resolved 
with antifilarial treatment [S35, S43, S193, S232]. Two patients 
had an acute thrombotic event in the ulnar vein [S148] and 
popliteal artery [S205].
There were 25 cases (16.2%) related to the nervous system 
[S11, S14, S28, S32, S55, S57, S66, S90, S100, S158, S159, S167, 
S223, S225, S257, S260, S261, S262, S266, S268, S272]. There 
were 9 cases presenting with spontaneous encephalitis (before 
Nervous System–Based
Manifestations (16.2%)
• Spontaneous encephalitis
• Nerve palsies
• Severe headaches
Cardiovascular
Manifestations (6.5%)
• Heart failure
• Endomycocardial
   fibrosis
• Thrombotic event
• Splenic lesions
• Ascites
• Arthralgia
• Acute septic joint
Gastrointestinal
Manifestations (6.5%)
Rheumatological Manifestations (12.3%)
Nonclassical Opthalmic
Manifestations (20.1%)
• Part ial loss of  vision
• Total loss of  vision
• Pleural eusion
• Pulmonary fibrosis
• Nephrotic syndrome
• Renal failure
• Tissue calcification
• Testicular swelling
• Infertility
Respiratory Manifestations (6.5%)
Renal Manifestations (9.7%)
Dermatological Manifestations (13.0%)
Reproductive System and Soft Tissue
Manifestations (5.8%)
• Pruritus
• Transient edemas
• Rashes
• Urticaria
Figure 2. The spectrum of atypical clinical manifestations of loiasis. Schematic visualization of some of the atypical presentations of loiasis identified through the system-
atic literature review, highlighting the key vital organs and systems involved (confirmed by presence of adult Loa loa and/or microfilarial stages), the percentage of patients 
presenting with manifestations pertaining to that system, and some of the most common atypical presentations observed for that system.
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any antifilarial treatment) [S158, S167, S223, S257, S260, S261, 
S268], of which 8 cases had mf in the cerebrospinal fluid (CSF) 
[S158, S167, S223, S257, S261, S268]. Two patients had severe 
headaches refractory to medical treatment that resolved with 
antifilarial therapy [S14, S90]. There were 4 cases of ulnar nerve 
palsies [S55, S57, S100, S159] and 1 median nerve palsy whose 
neurological deficit resolved after antifilarial treatment [S57]. 
One patient had neck pain caused by cervical nerve root irri-
tation with associated worms erupting from the overlying skin 
[S32]. One patient was diagnosed with an acute change in per-
sonality and psychotic polydipsia; the altered behavior resolved 
with antifilarial treatment [S272]. Three cases presented with 
dizziness, a change in hearing, or a change in fine motor skills, 
but there was no clear unifying diagnosis [S11, S28, S272].
There were 32 cases (20.8%) of ophthalmic manifestations 
outside the classical adult worm migration under the conjunc-
tiva [S26, S42, S73, S78, S93, S95, S108, S115, S123, S130, S145, 
S169, S182, S187, S190, S211, S236, S250, S259, S266]. Twenty-
one cases reported reduced/partial loss of vision [S73, S93, 
S123, S145, S169, S187, S190, S236, S259, S266], and 5 reported 
total (unilateral/bilateral) loss of vision [S26, S42, S78, S182, 
S211]. In the cases for which follow-up information was avail-
able, 9 patients had improvement in the loss of vision after treat-
ment and 7 did not. There were 5 cases of reduced/blurred/loss 
of vision in which an adult worm was identified in the anterior 
chamber of the eye [S42, S78, S93, S145, S190]; 2 of these dem-
onstrated an inflammatory membrane adherent to the anterior 
iris. An adult worm was seen in the posterior chamber in 1 case 
with loss of vision [S169]. Microfilariae were found in the ante-
rior and posterior segments of the eye in 5 cases [S169, S259]. In 
the remaining cases with loss of vision where the worm was not 
successfully visualized by the physician, a variety of patholo-
gies were described. These were chorioretinitis, corneal edema, 
posterior chamber opacification, vitreous hemorrhage, hem-
orrhagic retinopathy, retinal detachment, neovascularization, 
retinal artery occlusion, and uveitis. From the 32 patients with 
atypical ocular symptoms, there was no report of co-infections 
with other agents causing ocular manifestations such as 
Onchocerca volvulus and/or Chlamydia trachomatis, nor were 
onchocerciasis or trachoma mentioned as possible causes of 
the manifestations observed (Supplementary Data, “Atypical 
Ocular Manifestations,” Supplementary Table 1).
There were 20 cases (13.0%) of dermatological signs, with 8 
cases of L. loa worms perforating through the skin (without any 
preceding antifilarial treatment) [S26, S95, S96, S98, S141, S154, 
S156, S222]. Two patients experienced skin swellings, 1 nasal 
[S162] that was excised to identify a worm. The remaining cases 
were skin rashes of varying nature: transient urticarial rashes, 
widespread exanthema rashes, and multiple pruritic lesions. 
One patient suffered from a vasculitis-like syndrome in which 
a biopsy of the purpuric rash demonstrated infiltrative eosino-
phils [S189].
Of the 199 cases of eosinophilia, 182 (91.5%) did not have 
any other co-infecting helminth reported. Of the 16 cases with 
(helminth) co-infections (8.5%), 8 presented with Mansonella 
perstans [S192, S217, S218, S227, S254, S263, S273, S274], 1 with 
O. volvulus [S225], 6 with soil-transmitted helminths (round-
worm, whipworm, hookworm and threadworm) [S19, S198, 
S229, S260, S262, S272], and 2 with schistosomiasis [S232, 
S233] (Supplementary Data, “Eosinophilia and Co-Infections”).
Factors Associated With Atypical Loiasis Manifestations
Information on microfilarial densities and typical/atyp-
ical manifestations was available for 172 patients (informa-
tion on presence/absence of mf, but not on densities, was 
available for 276 patients). There was a statistically signifi-
cant positive association between blood microfilarial density 
categories (amicrofilaremic, low and high) and atypical presen-
tation (atypical or typical, P =  .001, Pearson’s chi-square test) 
(Supplementary Data, “Statistical Analysis,” Supplementary 
Table 2). Based on this, 2 multivariate logistic regression models 
(Models 1 and 2, Figure 3A) were constructed to quantify the 
impact of microfilarial load on atypical presentation, control-
ling for demographic variables.
Model 1 had presentation status (typical/atypical) as the out-
come variable and age, sex, residency status, and microfilarial 
density categories as covariates (n  =  154 individuals). Model 
2, a more restricted model, included individuals for whom the 
above information was available but who also had their eosin-
ophilia status determined (n  =  114 individuals). This second 
model was considered to control for the potential influence of 
eosinophilia status, suggesting, in light of recent findings, a role 
of eosinophils in pathologies arising from microfilarial infec-
tion in other filariae [20], as well as accounting for potential 
differences in eosinophil-associated processes between individ-
uals indigenous to L. loa–endemic areas and those temporarily 
residing in such areas [21].
The results of both models demonstrated a positive associ-
ation between blood microfilarial levels and atypical presenta-
tion (Figure 3B). Individuals with high microfilarial densities 
were more likely to present with atypical manifestations com-
pared with amicrofilaremic individuals (Model 1: OR, 9.20; 95% 
CI,  2.00–42.38; P  =  .004; Model 2: OR,  12.94; 95% CI,  1.72–
97.32; P  =  .01). Individuals with low microfilarial loads were 
not significantly more likely to present atypically compared 
with amicrofilaremic individuals (Model 1: P  =  .37; Model 2: 
P = .37). Analysis of Model 2, including eosinophilia status, in-
dicated that eosinophilia was not significantly associated with 
the risk of presenting with atypical manifestations (OR,  0.47; 
95% CI, 0.12–1.85; P = .28), although, interestingly, most indi-
viduals analyzed (86%) were eosinophilic (98/114).
Both models revealed differences in the propensity for dif-
ferent residency status groups to present atypically. Locals res-
iding in endemic countries were significantly more likely than 
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locals residing in nonendemic countries and expatriates to have 
atypical manifestations (Figure 3B). This effect is in addition 
to and independent of microfilarial load, although it should 
be noted that locals residing in endemic countries also had the 
highest average microfilarial densities (Figure 4), further com-
pounding their risk.
DISCUSSION
Although our work corroborates findings from previous reviews 
regarding the variation in loiasis clinical profiles across dif-
ferent residency groups [14, 22], its size and focus on nontypical 
presentations provide novel insight into poorly resolved aspects 
of loiasis clinical epidemiology. Specifically, it highlights that 
the range of pathologies associated with L.  loa infection is far 
broader than just Calabar swellings and eyeworm passage [23]. 
Although this may be due to a bias toward atypical manifest-
ations in the reports analyzed here (well-known manifestations 
not meriting case reports) [24, 25], their breadth is striking, 
and our work provides an important summary of such pres-
entations. The review identified numerous cases of vital organ 
involvement, such as heart, liver, respiratory, and renal sys-
tems associated with loiasis. In addition, 25/32 (78.1%) cases 
with atypical visual manifestations were associated with partial 
or total vision loss (without onchocerciasis and/or trachoma). 
Although we were unable to prove causality, the legitimacy of 
the association is supported by corroboration of mf presence in 
tissues other than blood, such as pleural and ascitic fluid, eye 
Model: Atypical Presentation ~Age + Sex + Residency Status
+ MF Levels (+ Eosinophilia Presence/Absence)
329 Patients
Overall
154 Individuals
Model 1
114 Individuals
Model 2
MF Levels MF Levels
Eosinophilia
Presence/Absence
A
B
Model 1
Microfilarial (MF) levels only
(n = 154 Individuals)
Model 2
Microfilarial (MF) Levels and
Eosinophilia (n = 114 Individuals)
Factor
Demographic
MF densities
Age (continuous) 1.02 (0.99–1.05)
1.94 (0.89–4.22)
Ref
Ref
1.45 (0.64–3.35)
9.20 (2.00–42.38)
Not included
1.95 (0.74–5.11)
9.24 (3.10–27.51)
Sex (female as ref)
Locals, nonendemic country
Expatriates
Locals, endemic country
Zero mf
Low mf
High mf
Eosinophilia
OR (95%CI) P Value
.17 .111.03 (0.99–1.07)
2.97 (1.09–8.07)
Ref
Ref
1.62 (0.56–4.68)
12.94 (1.72–97.32)
0.47 (0.12–1.85)
2.49 (0.75–8.25)
22.60 (4.92–103.78)
.18
.37
<.001b <.001b
.004b
.09 .03a
.13
NA NA
NA
NA
.37
.01b
NA
.28
OR (95%CI) P Value
Figure 3. Association between individual-level factors and atypical loiasis presentation. Schematic illustration of the 2 multivariate logistic regression models used to 
quantify the influence of various factors on atypical loiasis presentation (A) and the output of these models (B). Microfilarial (MF) density levels were categorised as zero (0 
mf/mL blood recorded), low (>0 but <8000 mf/mL blood), and high (≥8000 mf/mL blood). aIndicates statistical significance or near significance (P ≤ .05). bIndicates statistical 
significance (P ≤ .01). Abbreviations: CI, confidence interval; MF, microfilarial; mf, microfilariae; OR, odds ratio. 
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chambers, etc., and improvement or successful resolution of 
pathology upon antifilarial treatment (which would not have 
taken place were the mf found in these tissues simply the re-
sult of their migration to sites of abnormal anatomy). However, 
we acknowledge we do not, at present, fulfill all the criteria to 
support causality, particularly because of the scarcity of longi-
tudinal studies [5]. The proportion of cases with dermatolog-
ical presentations (13%) may seem somewhat small; however, 
as the review focused on signs rather than symptoms, it likely 
excluded cases of itching (not systematically recorded in the 
reports).
These atypical conditions are more common than previ-
ously perceived, with 47% of examined patients presenting with 
a manifestation(s) outside the classical Calabar swellings and 
eyeworm. Individuals residing in endemic countries were at the 
greatest risk of developing atypical manifestations. The results 
presented here likely represent an overestimation of the true 
prevalence of atypical manifestations due to (various sources 
of) bias (eg, locals familiar with classical signs may only consult 
if suffering from other symptoms, whereas expatriates/travelers 
may consult at the first sign of more typical manifestations). 
However, our aim was not to evaluate the true proportion of 
atypical manifestations of loiasis but to describe and summarize 
the breadth of these presentations and, importantly, to evaluate 
whether they were related to L. loa microfilarial density. Thus, 
although we acknowledge recruitment bias in the case reports, 
this does not impact the analyses performed, as patients did not 
know their microfilarial density at the time of consultation. We 
advocate that large-scale surveys (eg, [10]) be conducted to es-
timate rigorously the rates of atypical presentations in endemic 
areas. Notwithstanding these limitations, even a smaller per-
centage of individuals experiencing atypical manifestations of 
loiasis would represent a substantial number of people given 
that 14 million reside in areas of high loiasis prevalence and in-
tensity in Central Africa [2].
The analyses presented here also highlight that individuals 
with high microfilarial densities are at the greatest risk of suf-
fering atypical manifestations. Although an association between 
infection intensity and disease is typically assumed in parasitic 
infections, its demonstration is essential to link infection to 
morbidity and mortality. Further work (with larger sample sizes 
and greater statistical power) is needed to corroborate this as-
sociation (and to identify any dose–response relationship with 
microfilarial density). Heavy infection intensity was identified 
as a crucial factor in a recent study examining the influence 
of L.  loa microfilarial infection on increased risk of mortality 
[5]. Although the mechanism underpinning this increased risk 
remains unclear, possibilities include obstructive processes as-
sociated with parasite carriage [26] and/or more general inflam-
matory responses inducing pathogenic processes in various vital 
organs. León et al. [27] identified endomyocardial fibrosis in a 
patient from an endemic area who had L.  loa microfilaremia 
and marked eosinophilia.
As high microfilarial densities also increase the probability 
of SAEs after ivermectin treatment [8], targeted treatment of 
individuals most at risk may require drugs that are not strongly 
and/or fast-acting microfilaricidal. Evidence supports the use of 
albendazole in instances where other anthelmintics would be 
unsafe [28, 29], although questions remain surrounding the ef-
ficacy and optimal dosing regimen [30].
For those with lower microfilarial densities, ivermectin is 
highly efficacious at clearing L.  loa mf [31]. Recent studies in 
areas co-endemic for loiasis and onchocerciasis evaluating the 
impact of mass ivermectin treatment on microfilarial preva-
lence and intensity of loiasis have yielded promising results in 
terms of reductions in the prevalence of heavy microfilaremia 
[32] (although others have reported less clear-cut results on en-
tomological indicators of transmission [33]). However, not all 
areas endemic for loiasis are also co-endemic with onchocer-
ciasis and/or lymphatic filariasis [34, 35], and thus would not 
receive ivermectin or ivermectin plus albendazole treatment 
for these filariases. Hence, perhaps with the exception of those 
loiasis-only areas in which control programs for soil-transmitted 
helminthiases are being implemented using benzimidazole an-
thelmintics (to which albendazole belongs), our results suggest 
that substantial reductions in the burden of loiasis in these com-
munities could be achieved through campaigns targeting loi-
asis directly (through chemotherapeutic and/or tabanid control 
interventions) [1, 28–32, 36].
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Figure 4. Average microfilarial densities for each of the residency categories 
examined in the analyses. The mean microfilarial densities for each residency 
group, locals residing in endemic countries (n = 40), locals residing in nonendemic 
countries (n = 44), and expatriates (n = 81) were calculated as the arithmetic means 
of the reported microfilarial densities, quantified by microscope blood smear. Error 
bars represent the 95% confidence intervals calculated using bootstrapping (see the 
Supplementary Data, “Confidence Interval Calculation: Non-Parametric Bootstrap”). 
Abbreviation: mf, microfilariae.
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CONCLUSIONS
The work presented here suggests that conceptions of loiasis 
as a relatively benign infection are likely misplaced and em-
phasizes the public health importance of loiasis. Our results 
highlight the wide spectrum of clinical conditions associated 
with L.  loa carriage, including visual impairment and blind-
ness (typically disregarded as sequelae of loiasis). Although es-
timates of the burden of disease attributable to loiasis remain 
outstanding, these will likely be significantly higher than an-
ticipated. This will be especially true in communities bearing 
high microfilarial burdens, as severe manifestations of loiasis 
occur at higher frequencies in heavily infected individuals. We 
advocate that large-scale, community-wide (and ideally longi-
tudinal) studies be conducted in endemic regions to ascertain 
the true prevalence of atypical loiasis manifestations and the 
association between infection intensity and morbimortality to 
better understand the clinical and public health burden of lo-
iasis in its own right and not merely as an impediment to the 
control of other filarial diseases [37].
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